The metabolism of the orexin-1 selective receptor antagonist nivasorexant

References

• Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, de Lecea L. 2007. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature. 450(7168):420–424. doi: 10.1038/nature06310.
   PubMed Web of Science ®Google Scholar
• Borgland SL, Chang SJ, Bowers MS, Thompson JL, Vittoz N, Floresco SB, Chou J, Chen BT, Bonci A. 2009. Orexin A/hypocretin-1 selectively promotes motivation for positive reinforcers. J Neurosci. 29(36):11215–11225. doi: 10.1523/JNEUROSCI.6096-08.2009.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu L, Nguyen K, Fretland AJ. 2011. Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative ­extrapolation of human liver microsomal intrinsic clearance using ­recombinant cytochromes P450. Drug Metab Dispos. 39(3):373–382. doi: 10.1124/dmd.110.035147.
   PubMed Web of Science ®Google Scholar
• De Lecea L, Kilduff TS, Peyron L, Gao XB, Foye PE, Danielson PE, Fukuhara C, Battenberg ELF, Gautvik VT, Bartlett FS, et al. 1998. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 95(1):322–327. doi: 10.1073/pnas.95.1.322.
   PubMed Web of Science ®Google Scholar
• Dingemanse J, Cruz HG, Gehin M, Hoever P. 2014. Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazem. J Pharm Sci. 103(5):1548–1556. doi: 10.1002/jps.23916.
   PubMed Web of Science ®Google Scholar
• Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, et al. 2016. Suvorexant in patients with insomnia: pooled analysis of three-month data from phase-3 randomized controlled clinical trials. J Clin Sleep Med. 12(9):1215–1225. doi: 10.5664/jcsm.6116.
   PubMed Web of Science ®Google Scholar
• Hopf FW. 2020. Recent perspectives on orexin/hypocretin promotion of addiction-related behaviors. Neuropharmacology. 168:108013. doi: 10.1016/j.neuropharm.2020.108013.
   PubMed Web of Science ®Google Scholar
• Kärppä M, Yardley J, Pinner K, Filippov G, Zammit G, Moline M, Perdomo C, Inoue Y, Ishikawa K, Kubota N. 2020. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNISE 2. Sleep. 43(9):1–11. doi: 10.1093/sleep/zsaa123.
   Web of Science ®Google Scholar
• Landry I, Aluri J, Nakai K, Hall N, Miyajima Y, Ueno T, Dayal S, Filippov G, Lalovic B, Moline M, et al. 2021. Evaluation of the CYP3A and CYP2B6 drug-drug interaction potential of lemborexant. Clin Pharmacol Drug Dev. 10(6):681–690. doi: 10.1002/cpdd.915.
   PubMed Web of Science ®Google Scholar
• Matsuki T, Sakurai T. 2008. Orexins and orexin receptors: from molecules to integrative physiology. Results Probl Cell Differ. 46:27–55. doi: 10.1007/400_2007_047.
   PubMedGoogle Scholar
• McElroy SL, Coloma PM, Berger B, Guerdjikova AI, Joyce JM, Liebowitz MR, Pain S, Rabasa C. 2023. Efficacy, safety, and tolerability of nivasorexant in adults with binge eating disorder: a randomized, phase II proof of concept trial. Int J Eat Disord. 56(11):2120–2130. PMDI37584285. doi: 10.1002/eat.24039.
   PubMed Web of Science ®Google Scholar
• Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti CLA, Pain S, Seboek-Kinter D, Roth T, investigators 2022. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomized, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 21(2):125–139. doi: 10.1016/S1474-4422(21)00436-1.
   PubMed Web of Science ®Google Scholar
• Piccoli L, Micioni di Bonaventura MV, Cifani C, Costantini VJA, Massagrande M, Montanari D, Martinelli P, Antolini M, Ciccocioppo R, Massi M, et al. 2012. Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats. Neuropsychopharmacology. 37(9):1999–2011. doi: 10.1038/npp.2012.48.
   PubMed Web of Science ®Google Scholar
• Roth R, Schmidt G, Prud’homme A, Abele S. 2019. Highly selective synthesis of 2-(2H-1,2,3-triazole-2-yl)benzoic acids. Org Process Res Dev. 23(2):234–243. doi: 10.1021/acs.oprd.8b00349).
   Web of Science ®Google Scholar
• Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, et al. 1998. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 92(4):573–585. doi: 10.1016/s0092-8674(00)80949-6.
   PubMed Web of Science ®Google Scholar
• Seglen PO, Fossa J. 1978. Attachment of rat hepatocytes in vitro to substrata of serum protein, collagen, or concanavalin A. Exp Cell Res. 116(1):199–206. doi: 10.1016/0014-4827(78)90076-9.
   PubMed Web of Science ®Google Scholar
• Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM. 2000. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 27(3):469–474. doi: 10.1016/s0896-6273(00)00058-1.
   PubMed Web of Science ®Google Scholar
• Treiber A, Aissaoui H, Delahaye S, Glutz S, Grimont J, Müller C, Seeland S, Siefken V, Boss C. 2023. CYP3A4 catalyzes the rearrangement of the dual orexin receptor antagonist daridorexant to 4-hydroxypiperidinol metabolites. ChemMedChem. 18(10):e202300030. doi: 10.1002/cmdc.202300030.
   PubMedGoogle Scholar
• Tschirret-Guth RA, Wood HB. 2003. Substituent effect on the reductive N-dearylation of 3-(indol-1-yl)-1,2-benzisooxazoles by rat liver microsomes. Drug Metab Dispos. 31(8):999–1004. doi: 10.1124/dmd.31.8.999.
   PubMed Web of Science ®Google Scholar
• Williams JT, Bolli MH, Brotschi C, Roch C, Sifferlen T, Steiner MA, Treiber A, Gatfield J, Boss C. 2024. Discovery of nivasorexant (ACT-539313): the first selective orexin-1 receptor antagonist (SO1RA) investigated in clinical trials. J Med Chem. doi: 10.1021/acs.jmedchem.3c01894.
   Google Scholar
• Wong KK, Ng SY, Lee LT, Ng HK, Chow BK. 2011. Orexins and their receptors from fish to mammals: a comparative approach. Gen Comp Endocrinol. 171(2):124–130. doi: 10.1016/j.ygcen.2011.01.001.
   PubMed Web of Science ®Google Scholar
• Wrishko RE, McCrea JB, Yee KL, Liu W, Panebianco D, Mangin E, Chakravarthy M, Martinez-Cantarin WK, Kraft WK. 2019. Effect of CYP3A4 inhibition and induction on the pharmacokinetics of suvorexant: two phase I, open-label, fixed-sequence trials in healthy subjects. Clin Drug Investig. 39(5):441–451. doi: 10.1007/s40261-019-00764-x.
   PubMed Web of Science ®Google Scholar